Sarepta Therapeutics (SRPT) Depreciation & Amortization (CF) (2010 - 2026)

Sarepta Therapeutics' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $10.6 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 6.17% year-over-year to $10.6 million; the TTM figure through Mar 2026 stood at $45.1 million (up 15.86% YoY), while the FY2025 annual figure was $44.5 million, up 18.02% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $10.6 million, up from $5.3 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $18.4 million in Q3 2025, with the low at $5.3 million in Q4 2025.
• The 5-year median for Depreciation & Amortization (CF) is $10.6 million (2026), against an average of $10.5 million.
• Peak annual rise in Depreciation & Amortization (CF) reached 88.15% in 2025, while the deepest fall reached 49.76% in 2025.
• Sarepta Therapeutics' Depreciation & Amortization (CF) stood at $10.6 million in 2022, then rose by 7.76% to $11.4 million in 2023, then declined by 8.06% to $10.5 million in 2024, then sank by 49.76% to $5.3 million in 2025, then jumped by 101.68% to $10.6 million in 2026.
• Business Quant data shows SRPT's Depreciation & Amortization (CF) at $10.6 million in Q1 2026, $5.3 million in Q4 2025, and $18.4 million in Q3 2025.